News | September 09, 2007

New Treatment for PAD Implanted

September 7, 2007 - Gary Ansel, M.D., Riverside Methodist Hospital, successfully implanted the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface, a stent graft designed to open blockages in the superficial femoral artery in the thigh, which is used to treat a common form of peripheral arterial disease (PAD).

The stent is designed to improve outcomes, speeds recovery and may minimize the risk of complications. The device, manufactured by W.L. Gore & Associates in Flagstaff, AZ, and FDA approved in August to relieve hardening of the thigh artery, uses the same material that is in rain suit for golf. The Gore-Tex fabric stops tissue from growing inside the tube and has the blood thinning medication Heparin as part of the device lining. The Gore-Tex keeps the Heparin anchored to its surface, allowing the medication to interact with the blood reportedly for years.

The stent placement is a less invasive alternative to bypass surgery that requires an incision or several incisions over the entire length of the thigh with a four- to six-week recovery. Ansel inserted the device in the patient’s leg in 20 minutes through a puncture the size of a ballpoint pen tip.

For more information: www.ohiohealth.com


Related Content

Feature | Stents Peripheral | Dave Fornell, Editor

November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) ...

Home November 06, 2019
Home
Technology | Stents Peripheral

October 5, 2018 — Veryan Medical Ltd has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent System ...

Home October 05, 2018
Home
News | Stents Peripheral

April 27, 2018 — Intact Vascular Inc. recently closed a Series C financing totaling $20 million. This financing is ...

Home April 27, 2018
Home
News | Stents Peripheral

July 26, 2017 — Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee ...

Home July 26, 2017
Home
News | Stents Peripheral

July 14, 2017 — Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational ...

Home July 14, 2017
Home
News | Stents Peripheral

April 28, 2017 — Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting ...

Home April 28, 2017
Home
News | Stents Peripheral

March 16, 2017 — W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular ...

Home March 16, 2017
Home
News | Stents Peripheral

March 2, 2017 — Intact Vascular Inc. announced in February that its Tack Optimized Balloon Angioplasty II Below the Knee ...

Home March 02, 2017
Home
News | Stents Peripheral

December 13, 2016 — Biotronik announced the presentation of data confirming the efficacy of the Pulsar-18 bare metal ...

Home December 13, 2016
Home
News | Stents Peripheral

December 8, 2016 — LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow ...

Home December 08, 2016
Home
Subscribe Now